Other pre-clinical studies have reported that in certain cases, HDL may drive the development of breast cancer, particularly in circumstances when breast tumor cells overexpress the HDL receptor, SR-B1, since this receptor can mediate both survival signaling and uptake of cholesterol fueling tumor growth (173–177). Here, SCARB1 is linked to neoplasm.